STRategies to Improve Donor ExperienceS (STRIDES)

  • Research type

    Research Study

  • Full title

    STRategies to Improve Donor ExperienceS (STRIDES): A cluster randomised trial to evaluate interventions to prevent vasovagal reactions among whole blood donors

  • IRAS ID

    243737

  • Contact name

    Emanuele Di Angelantonio

  • Contact email

    ed303@medschl.cam.ac.uk

  • Sponsor organisation

    NHS Blood and Transplant

  • Duration of Study in the UK

    10 years, 0 months, 1 days

  • Research summary

    Feeling faint and fainting (i.e., vasovagal reactions [VVRs]) are the most common acute complications of blood donation. There is, however, limited reliable evidence about how to prevent VVRs. We will, therefore, conduct a powerful pragmatic trial embedded within NHS Blood and Transplant (NHSBT), drawing on input provided after extensive consultation with a variety of stakeholders, including blood donors, NHSBT staff and leadership, and a team of multi-disciplinary applied health researchers. The trial design has been tailored to the specific needs and circumstances of NHSBT, and to the particular interventions to be evaluated.

    Following a 4-month feasibility phase, we will conduct a cluster-randomised cross-over/stepped-wedge factorial trial over 3 years involving the entire blood service. We will randomise ~72 blood donation teams across England (i.e., the study’s “clusters”) to combinations of the following four trial interventions compared with current NHSBT practice:

    1) isotonic hydration before donation: 500ml isotonic drink vs 500ml plain water;
    2) time on donation chair after donation: 3-minutes before standing vs 2-minutes;
    3) modified applied muscle tension (AMT): new AMT vs current practice of AMT;
    4) psychosocial intervention: preparatory materials vs nothing.

    After 36-months of monitoring, the primary endpoint will be the number of in-session VVRs with loss of consciousness. Secondary endpoints will include: all in-session VVRs; delayed VVRs; and any in-session non-VVR adverse events or reactions. As key concurrent goals are to advance understanding of the determinants of VVRs and to develop prevention strategies for VVRs tailored to specific donor sub-populations (e.g., based on demographic, biological, psychosocial, and other characteristics) and to conduct more detailed studies through re-contact of subsets of donors, we will create a BioResource that underpins these efforts.

    The study will: yield evidence-based policies to reduce VVRs; lead to improvements in donor-health, experience, and service efficiency; reduce NHSBT’s medicolegal liabilities; and advance scientific understanding.

  • REC name

    East of England - Cambridge South Research Ethics Committee

  • REC reference

    18/EE/0284

  • Date of REC Opinion

    21 Nov 2018

  • REC opinion

    Further Information Favourable Opinion